丁喹伦 | 59184-78-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 丁喹伦
• 中文别名: 丁脲哌喹啉
• 英文名称: 1-butyl-3-[1-(6,7-dimethoxy-quinazolin-4-yl)-piperidin-4-yl]-urea
• 英文别名: buquineran；1-butyl-3-[1-(6,7-dimethoxyquinazolin-4-yl)piperidin-4-yl]urea
• CAS: 59184-78-0
• 化学式: C₂₀H₂₉N₅O₃
• 分子量: 387.482
• InChiKey: CPZHDDGPHQRMEJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  88.6
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Pharmaceutical preparation comprising an active dispersed on a matrix
  申请人：——

  公开号：US20040058896A1

  公开（公告）日：2004-03-25

  The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In the new preparation an active ingredient is present essentially uniformly dispersed in an excipient matrix composed of one or more excipients selected from the group of fatty alcohol, triglyceride, partial glyceride and fatty acid ester.

  本发明涉及制药技术领域，描述了一种新的有利的活性成分制备方法。这种新的制备方法适用于生产大量的药物剂型。在这种新的制备方法中，活性成分基本上均匀地分散在由脂肪醇、甘油三酯、部分甘油酯和脂肪酸酯等多种赋形剂中选择的一种或多种赋形剂组成的赋形剂基质中。
• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• Quinazoline cardiac stimulants
  申请人：Pfizer Limited

  公开号：EP0094766A2

  公开（公告）日：1983-11-23

  Quinazoline cardiac stimulants of the formula:- and their pharmaceutically acceptable salts, wherein X is a straight or branched chain alkylene group having a total of from 1 to 4 carbon atoms; and Y is a group of the formula:- where R1 is H or C1-C4 alkyl and R2 and R3 are each independently H or CH3; processes for their preparation; and pharmaceutical compositions containing them.

  式中的喹唑啉类强心剂：- 及其药学上可接受的盐类，其中 X 是具有 1 至 4 个碳原子的直链或支链亚烷基；Y 是如下式的基团 及其药学上可接受的盐，其中 X 是直链或支链亚烷基，具有 1 至 4 个碳原子； Y 是式中的一个基团 其中 R1 是 H 或 C1-C4 烷基，R2 和 R3 各自独立地是 H 或 CH3；它们的制备工艺；以及含有它们的药物组合物。
• Advanced drug development and manufacturing
  申请人：Los Alamos National Security, LLC

  公开号：EP2511844A2

  公开（公告）日：2012-10-17

  There is described an apparatus for measuring protein characteristics comprising an X-ray fluorescence (XRF) spectrometer comprising a source of polychromatic X-rays, an X-ray detector, a protein, a molecule that has been exposed to and at least weakly binds to the protein, a plurality of X-ray fluorescence signal data obtained by irradiating chemical elements in the protein and molecule with the polychromatic X-rays and a security system for maintaining records for the data from the plurality of X-ray fluorescence signal measurements. There is also described an x-ray microscope for measuring a sample.

  描述了一种测量蛋白质特性的仪器，该仪器包括一个 X 射线荧光 (XRF) 光谱仪，其中包括一个多色 X 射线源、一个 X 射线探测器、一个蛋白质、一个已暴露于该蛋白质并至少与该蛋白质弱结合的分子、通过用多色 X 射线照射蛋白质和分子中的化学元素而获得的多个 X 射线荧光信号数据，以及一个用于维护多个 X 射线荧光信号测量数据记录的安全系统。此外，还介绍了一种用于测量样品的 X 射线显微镜。
• NOVEL COMPOUNDS AND METHODS FOR MODULATING UBIQUITINATION
  申请人：Johann Wolfgang Goethe-Universität Frankfurt am Main

  公开号：EP3299460A1

  公开（公告）日：2018-03-28

  The present invention pertains to the modification of the eukaryotic ubiquitin system by using the bacterial virulence factor SdeA and variants and mutants thereof. The invention is based on the phosphodiesterase activity of SdeA, which catalyzes a phospho-ribosylation (or simply "ribosylation") event of ubiquitin and ubiquitin-like proteins. The invention provides SdeA proteins and mutants without said phosphodiesterase activity, as well as medical applications of these recombinant proteins, their encoding nucleic acids, ribosylated ubiquitin proteins, and compounds which may act as selective or non-selective phosphodiesterase inhibitors.

  本发明涉及利用细菌毒力因子 SdeA 及其变体和突变体对真核生物泛素系统进行修饰。 本发明以 SdeA 的磷酸二酯酶活性为基础，SdeA 可催化泛素和泛素样蛋白的磷酸核糖化（或简称 "核糖化"）过程。 本发明提供了没有上述磷酸二酯酶活性的 SdeA 蛋白和突变体，以及这些重组蛋白、其编码核酸、核糖基化泛素蛋白和可作为选择性或非选择性磷酸二酯酶抑制剂的化合物的医学应用。